Biosimilars Might Ultimately Lower Economic Barriers To Treatment For Hemophiliac Youths In Asia
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Although sporadic advances in treating hemophilia are being led by scientists and state health officials across pockets of Asia, including inside China, most of the people afflicted with the genetic blood disorder on the planet's most populous continent will die while still children, according to a leading authority on the disease